You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
06. Ovarian cancer
#312 Oncological safety of fertility preservation treatment in ovarian cancer
Free
  1. Marta Heras1,
  2. Leticia Azcona2,
  3. Octavio Arencibia3,
  4. Lucas Minig4,
  5. Lola Martí5,
  6. Alicia Hernandez6,
  7. Arantxa Lekuona7,
  8. Isabel Ñiguez8,
  9. Blanca Gil- Ibañez9,
  10. Berta Diaz- Feijóo10,
  11. Laia Ribot11,
  12. Maria Nieves Cabezas12,
  13. Marta Lamarca13,
  14. Mónica Bellón14,
  15. Amira Alkourdi15,
  16. Laura Cárdenas16,
  17. Ana Boldo17,
  18. Joana Amengual18,
  19. Mikel Gorostidi7 and
  20. Ignacio Zapardiel6
  1. 1Hospital Santa Cristina, Madrid, Spain
  2. 2Hospital Virgen Macarena, Sevilla, Spain
  3. 3Hospital Insular Materno Infantil de Canarias, Gran Canaria, Spain
  4. 4IMED Hospitales, Valencia, Spain
  5. 5Hospital Bellvitge, Barcelona, Spain
  6. 6Hospital La Paz, Madrid, Spain
  7. 7Hospital Donostia San Sebastián, San Sebastián, Spain
  8. 8Hospital Virgen de la Arrixaca, Murcia, Spain
  9. 9Hospital 12 de Octubre, Madrid, Spain
  10. 10Hospital Clinic, Barcelona, Spain
  11. 11Hospital Parc Tauli, Sabadell, Spain
  12. 12Hospital Virgen de la Macarena, Sevilla, Spain
  13. 13Hospital Miguel Servet, Zaragoza, Spain
  14. 14Hospital Clínico San Carlos, Madrid, Spain
  15. 15Hospital Virgen de las Nieves, Granada, Spain
  16. 16Hospital Josep Trueta, Girona, Spain
  17. 17Hospital La Plana, Villareal, Spain
  18. 18Hospital Son Espases, Mallorca, Spain

Abstract

Introduction/Background To assess the safety of fertility sparing treatments for early-stage ovarian cancer in women younger than 45 years.

Methodology We performed a retrospective multicenter study including women from 18 to 45 years old diagnosed of early-stage (FIGO I-II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced-stage (FIGO III-IV). All perioperative characteristics and follow-up were collected and analyzed. Standard staging surgery (SSS) was compared to fertility sparing surgery (FSS) in terms of oncological outcomes.

Abstract #312 Figure 1
Abstract #312 Figure 1

Kaplan Meier survival based on histology and type of surgery

Results A total of 630 women were included; 546 (86.7%) were stage I. The median tumor size was 94 mm (IQR 25–75: 60–139). The median patients´ age was 38.7 years old (IQR 25–75: 33.4–42.7) with a median body mass index of 23.6 kg/m2 (IQR 25–75: 21.2–27.7). Among all patients, 469 (74.4%) underwent SSS and 161 (25.6%) FSS. Up to 351 patients (56.3%) did not have children, but only 12 (1.92%) had oocyte preservation before treatment. Patients in the FSS group compared to SSS group showed a non- significant difference in recurrences (8.7% vs. 11.8%, respectively; p=0.31) and deaths (1.2% vs. 5.5%, respectively; p=0.087) during the follow-up. No significant differences were found between epithelial and non-epithelial ovarian cancer both in recurrences (9.1% vs. 8.3%, respectively; p=0–998) and deaths (4% vs. 3.6%, respectively; p=0.997) among patients who underwent FSS.

Conclusion FSS seems a safe option for treatment of early-stage ovarian cancer in patients who want to preserve fertility; either for epithelial and non-epithelial histology.

Disclosures None

https://doi.org/10.1136/ijgc-2023-ESGO.558

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.